Incidencia y características clínicas y epidemiológicas del carcinoma de nasofaringe en Cantabria en 2014

  1. RÍO-GONZÁLEZ, Gloria del 1
  2. Patricia CORRIOLS-NOVAL
  3. Aiara VIANA-CORA
  4. Nathalia CASTILLO-LEDESMA 1
  5. Eugenia Carmela LÓPEZ-SIMÓN 1
  6. Carmelo MORALES-ANGULO
  1. 1 Hospital Universitario Marqués de Valdecilla
    info

    Hospital Universitario Marqués de Valdecilla

    Santander, España

    ROR https://ror.org/01w4yqf75

Aldizkaria:
Revista ORL

ISSN: 2444-7986,  2444-7986

Argitalpen urtea: 2019

Alea: 10

Alea: 3

Orrialdeak: 171-180

Mota: Artikulua

DOI: 10.14201/ORL.19707 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Beste argitalpen batzuk: Revista ORL

Garapen Iraunkorreko Helburuak

Laburpena

Introduction and Objective: The objective of this study was to describe the clinic-epidemiological characteristics of the nasopharyngeal carcinoma in Cantabria (Spain) and to compare it with previous studies performed. Material and methods: A retrospective study of nasopharyngeal carcinomas diagnosed in Marqués de Valdecilla Hospital (Santander, Cantabria, Spain) between 2004 and 2015 was made, determining the following variables: age, occupation, toxics, outcome symptoms, treatment and clinical evolution. Results: 45 patients with ages range between 35 and 85 were diagnosed of nasopharyngeal carcinoma, with an incidence of 0,71/100000H/year. 38 were men (84,5%) and 7 were women (15,6%). The fifties decade was the most frequent period of diagnosis. Otological symptoms were the main clinical outcome (40%), followed by cervical adenopathy (26,6%). Undifferentiated carcinoma was the most common histological type (68,9%), being diagnosed in advanced stages. Conclusions: Nasopharyngeal carcinoma is an uncommon tumour in Cantabria being more frequent in males in their fifties. Its clinical presentation, often nonspecific, results in advanced stages diagnose. The most common histological type (undifferentiated carcinoma).

Erreferentzia bibliografikoak

  • Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002. Cancer Incidence, mortality and prevalence worlwide IARC. CancerBase N, versión 2.0. Lyon: IARC Press 2004. Disponible en: https://gco.iarc. fr/. [Citado el 05/01/2019].
  • Escamilla Carpintero Y, Aguilà Artal AF, Bonfill Abella T, Mur Restoy E, Díaz Argüello JJ. Revisión retrospectiva de 23 años en nuestro centro. ORL Aragón. 2015;18:15-20.
  • Yu MC: Nasopharyngeal carcinom. Epidemiology and dietary factors, IARC Sci Publ 1991;105:39-47.
  • Morales-Angulo C, Megía López R, Rubio Suárez A, Rivera Herrero F, Rama J. Carcinoma de Nasofaringe en Cantabria. Acta Otorrinolaring Esp. 1999;50:381-86.
  • Lester D. Thompson R. Update on Nasopharyngeal Carcinoma. Head Neck Pathol. 2007;1:81–6.
  • Morales-Angulo C, Megía López R, Rubio Suárez A, Bezos. Capelastegui JT, Rama J. Diagnóstico precoz del carcinoma de nasofaringe. An Otorrinolaringol Ibero Am. 2001;28:317-23.
  • Mills S. Metatastatic undifferentiated carcinoma, lymphoepithelioma type. Arch Otolaryngol. 1982;108: 258-60.
  • Simons MJ, Chan SH, Wee GB, Shanmugaratnam K, Goh EH, Ho JH et al Nasopharyngeal carcinoma and histocompatibility antigens. IARC Sci Publ. 1978;20:271-82.
  • Simons MJ, Wee GB, Singh D, Dharmalingham S, Yong NK, Chau JC et al. Immunogenetic aspects of nasopharyngeal carcinoma. V. Confirmation of a Chinese-related HLA profile [A2, Singapore 2] associated with an increased risk in Chinese for nasopharyngeal carcinoma. Natl Cancer Inst Monogr. 1977;47:147-51.
  • Indudharan R, Valuyeetham M, Kannan T, Sidek DS. Nasopharyngeal carcinoma: clinical trends. J Otol Rhinl Laryngol. 1997;111:724-9.
  • Rassekh CH, Rady PL, Arany I, Tyring SK, Knudsen S, Calhoun KH et al. Combined Epstein-Barr virus and human papillomavirus infection in nasopharyngeal carcinoma. Laryngoscope. 1998;108:362-7.
  • Lin JC1, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS et al. Quantification of plasma Epstein Barr virus DNA in patients with advanced nasopharyngeal carcinoma, N Engl J Med. 2004;350: 2461-70.
  • Murono S1, Yoshizaki T, Tanaka S, Takeshita H, Park CS, Furukawa M. Detection of Epstein Barr virus in nasopharyngeal carcinoma by in situ hybridation and polymerase chain reaction. Laryngoscope 1997;107:523-6.
  • Harding U, Nielsen H, Daugaard S. Human papillomavirus types 11 and 16 detected in nasopharyngeal carcinoma by the polimerase chain reaction. Laryngoscope. 1994;104:99-102.
  • Nam JM, McLaughlin JK, Blot WJ. Cigarette smoking, alcohol, and nasopharyngeal carcinoma: a case-control study among U.S. whites. Natl Cancer Inst. 1992;84:619-22.
  • Pensak ML. Otolaryngology cases, Nasopharyngeal cancer.1º ed. USA. Thieme; 2010.
  • Sanguineti G1, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH et al. Carcinoma of the nasopharynx treated by radiotherapy alone. Determinants of local and regional control. Int J Radiat ncol Biol Phys. 1997;37:985-96.
  • Huang HY, Wilkie DJ, Schubert MM, Ting LL. Symptom profile of nasopharyngeal cancer patients during radiation therapy Cancer Pract. 2000;8:274-81.
  • Poon PY, T Sang VH, Munk PL. Tumour extent and T stage of nasopharyngeal carcinoma. A comparison of magnetic resonance imaging and computed tomographic findings, Can Assoc Radiol J. 2000;51:287-95.
  • ICANE. Población de Cantabria 2014 Disponible en: https://www.icane.es/. [Citado el 23 Abril 2015].
  • Edge SB, Comptom CC. The AJCC cancer staging manual. 8th ed. Springer; 2009.
  • Ferlito A, Elsheikh MN, Manni JJ, Rinaldo A. Paraneoplastic syndromes in patients with primary head and neck cancer. Eur Arch Otorhinolaryngol. 2007;264:211–22.
  • Iannessi A, Ouvrier MJ, Thariat J, Marcy PY. Imaging in head and neck cancers. Bull Cancer. 2014 1;101:469-80.
  • Al-Sarraf M1, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cáncer. Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16: 1310-7.
Datuen iturria: Dialnet